[27P2-pm2] Clinical Pharmacy 3

[27P2-pm2-100S] Biomarker for atezolizumab/ bevacizumab combination therapy with soluble MICA in patients with HCC

○Yuka Kyoso¹, Kunihide Mohri^1,2, Yasuaki Tatsumi¹, Takanori Wakui², Hidenari Nagai², Koji Higai¹ (1. Faculty of Pharmaceutical Sciences, Toho university, 2. Department of Internal Medicine (Omori), School of Medicine, Toho University)